亚虹医药：关于APL-2401临床试验申请获得国家药品监督管理局批准的公告

Group 1 - The core announcement is that Yahui Pharmaceutical has received approval from the National Medical Products Administration (NMPA) for its clinical trial application for APL-2401 (also known as ASN-8639 tablets) [2] - The clinical trial will focus on patients with advanced solid tumors driven by FGFR2/3 [2] - This approval marks a significant step for the company in advancing its drug development pipeline [2]